These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 26282797)

  • 1. Squaric acid sensitization is not required for response in the treatment of alopecia areata.
    Vedak P; Kroshinsky D
    J Am Acad Dermatol; 2015 Sep; 73(3):471-6. PubMed ID: 26282797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical squaric acid dibutylester therapy for alopecia areata: a double-sided patient-controlled study.
    Chua SH; Goh CL; Ang CB
    Ann Acad Med Singap; 1996 Nov; 25(6):842-7. PubMed ID: 9055014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice.
    Freyschmidt-Paul P; Sundberg JP; Happle R; McElwee KJ; Metz S; Boggess D; Hoffmann R
    J Invest Dermatol; 1999 Jul; 113(1):61-8. PubMed ID: 10417620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical therapy of alopecia areata with squaric acid dibutylester.
    Case PC; Mitchell AJ; Swanson NA; Vanderveen EE; Ellis CN; Headington JT
    J Am Acad Dermatol; 1984 Mar; 10(3):447-50. PubMed ID: 6725657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of severe alopecia areata with squaric acid dibutylester in pediatric patients.
    Orecchia G; Malagoli P; Santagostino L
    Pediatr Dermatol; 1994 Mar; 11(1):65-8. PubMed ID: 8170854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of topical immunotherapy with squaric acid dibutylester for alopecia areata in Japanese patients.
    Sakai K; Fukushima S; Mizuhashi S; Jinnin M; Makino T; Inoue Y; Ihn H
    Allergol Int; 2020 Apr; 69(2):274-278. PubMed ID: 31767273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of alopecia areata with diphencyprone].
    Suditu G; Toma A; Voiculescu M
    Rev Med Chir Soc Med Nat Iasi; 2001; 105(4):760-2. PubMed ID: 12092234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalisation of hair follicle morphology in C3H/HeJ alopecia areata mice after treatment with squaric acid dibutylester.
    Gardner S; Freyschmidt-Paul P; Hoffmann R; Sundberg JP; Happle R; Lindsey NJ; Tobin DJ
    Eur J Dermatol; 2000 Aug; 10(6):443-50. PubMed ID: 10980465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies.
    Morita K; Nakamura M; Nagamachi M; Kishi T; Miyachi Y
    J Dermatol; 2002 Oct; 29(10):661-4. PubMed ID: 12433000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of alopecia areata with squaric acid dibutylester.
    Micali G; Cicero RL; Nasca MR; Sapuppo A
    Int J Dermatol; 1996 Jan; 35(1):52-6. PubMed ID: 8838932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of alopecia areata with squaric acid dibutylester.
    Caserio RJ
    Arch Dermatol; 1987 Aug; 123(8):1036-41. PubMed ID: 3307636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic approach with squaric acid dibutylester for steroid resistant-alopecia areata incognita: A pilot study of a single center.
    Starace M; Vezzoni R; Alessandrini A; Bruni F; Carpanese MA; Misciali C; Sechi A; Piraccini BM
    Dermatol Ther; 2021 Sep; 34(5):e15096. PubMed ID: 34390608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical immunotherapy with squaric acid dibutylester: unusual hair pigmentary changes in two cases of alopecia areata.
    Mastrolonardo M; Diaferio A
    J Eur Acad Dermatol Venereol; 2002 Mar; 16(2):186. PubMed ID: 12046838
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in Alopecia areata and factors influencing the outcome.
    Ajith C; Gupta S; Kanwar AJ
    J Drugs Dermatol; 2006 Mar; 5(3):262-6. PubMed ID: 16573260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population.
    Aghaei S
    BMC Dermatol; 2005 May; 5():6. PubMed ID: 15918897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial.
    Dall'oglio F; Nasca MR; Musumeci ML; La Torre G; Ricciardi G; Potenza C; Micali G
    J Dermatolog Treat; 2005 Feb; 16(1):10-4. PubMed ID: 15897160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical immunotherapy of alopecia areata. A follow-up study.
    Valsecchi R; Cainelli T; Foiadelli L; Rossi A
    Acta Derm Venereol; 1986; 66(3):269-72. PubMed ID: 2426909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified immunotherapy for alopecia areata.
    Yoshimasu T; Furukawa F
    Autoimmun Rev; 2016 Jul; 15(7):664-7. PubMed ID: 26932732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis.
    Lee S; Kim BJ; Lee YB; Lee WS
    JAMA Dermatol; 2018 Oct; 154(10):1145-1151. PubMed ID: 30073292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discoid lupus erythematosus exacerbated by contact dermatitis caused by use of squaric acid dibutylester for topical immunotherapy in a patient with alopecia areata.
    Shimaoka Y; Hatamochi A; Hamasaki Y; Suzuki H; Ikeda H; Yamazaki S
    J Dermatol; 2008 Mar; 35(3):151-3. PubMed ID: 18346258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.